Takahashi N, Aramaki Y, Tsuchiya S
Tokyo College of Pharmacy, Japan.
J Pharmacobiodyn. 1990 Jul;13(7):414-20. doi: 10.1248/bpb1978.13.414.
An animal disease model of allergic rhinitis was developed with Brown Norway (BN) rat, a high immunoglobulin E responder strain. BN rats were immunized with ovalbumin (OA) and made to suffer from allergic rhinitis. The severity of allergic rhinitis was assessed by determining the extent of the three kinds of markers, Evan's blue, histamine and N-acetyl-beta-D-glucosaminidase, released into the nasal perfusate following the OA challenge to the nasal cavity of OA-sensitized BN rats. This experimental system was appreciated by antiallergic drugs; chlorpheniramine maleate inhibited the release of Evan's blue and elevated that of histamine, but did not affect the N-acetyl-beta-D-glucosaminidase level. Halopredone acetate inhibited the releases of all the three markers. The estimation of the released markers using allergic rhinitis brought about in BN rats was found to be a useful experimental system for evaluating the effect of drugs on allergic rhinitis.
利用高免疫球蛋白E反应性品系的棕色挪威（BN）大鼠建立了变应性鼻炎动物疾病模型。用卵清蛋白（OA）对BN大鼠进行免疫，使其患上变应性鼻炎。通过测定在对OA致敏的BN大鼠鼻腔进行OA激发后，释放到鼻腔灌洗液中的三种标志物伊文思蓝、组胺和N - 乙酰 - β - D - 氨基葡萄糖苷酶的程度，来评估变应性鼻炎的严重程度。该实验系统对抗变应性药物有反应；马来酸氯苯那敏抑制伊文思蓝的释放并提高组胺的释放，但不影响N - 乙酰 - β - D - 氨基葡萄糖苷酶水平。醋酸卤泼尼龙抑制所有三种标志物的释放。发现利用BN大鼠诱发的变应性鼻炎来估计释放的标志物，是评估药物对变应性鼻炎疗效的有用实验系统。
